A PHASE 1, OPEN-LABEL, SINGLE DOSE STUDY TO INVESTIGATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF ZAVEGEPANT INTRANASAL ADMINISTRATION IN HEALTHY CHINESE ADULT PARTICIPANTS
Latest Information Update: 08 Jan 2025
At a glance
- Drugs Zavegepant (Primary)
- Indications Allergic asthma; COVID-19 respiratory infection; Migraine
- Focus Pharmacokinetics
- Sponsors Pfizer
- 21 Dec 2023 Status changed from active, no longer recruiting to completed.
- 21 Nov 2023 Planned End Date changed from 10 Feb 2024 to 29 Nov 2023.
- 21 Nov 2023 Planned primary completion date changed from 10 Feb 2024 to 29 Nov 2023.